MedTrace Logo

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

NCT02721069 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2022-01-31

Study results available
· View outcomes & findings →

Summary

This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1

Conditions

  • Acute Repetitive Seizures
  • Breakthrough Seizures

Interventions

DRUG

NRL-1

Sponsors & Collaborators

  • Neurelis, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-11
Primary Completion
2020-06-17
Completion
2020-07-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02721069 on ClinicalTrials.gov